
    
      This is a three-part dose escalation and dose expansion Phase 1 study of ASTX660 alone and in
      combination with ASTX727 in adults with R/R AML.

      Part 1 is an open-label, single arm, dose escalation with ASTX660 in combination with ASTX727
      at the standard fixed dose combination (FDC).

      Part 2 is an open-label, randomized, dose escalation intended to evaluate ASTX660 as a
      monotherapy and ASTX660 in combination with ASTX727 FDC.

      Part 3 is an exploratory single arm dose expansion to further expand the number of
      participants treated with ASTX660 in combination with ASTX727 FDC.
    
  